Innovita Biological Technology Past Earnings Performance
Past criteria checks 5/6
Innovita Biological Technology has been growing earnings at an average annual rate of 7.4%, while the Medical Equipment industry saw earnings growing at 6.1% annually. Revenues have been growing at an average rate of 9.9% per year. Innovita Biological Technology's return on equity is 16.2%, and it has net margins of 46.1%.
Key information
7.4%
Earnings growth rate
-8.0%
EPS growth rate
| Medical Equipment Industry Growth | 16.0% |
| Revenue growth rate | 9.9% |
| Return on equity | 16.2% |
| Net Margin | 46.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Innovita Biological Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 720 | 332 | 138 | 80 |
| 30 Jun 24 | 676 | 303 | 134 | 75 |
| 31 Mar 24 | 625 | 266 | 134 | 65 |
| 31 Dec 23 | 478 | 174 | 104 | 53 |
| 30 Sep 23 | 415 | 110 | 100 | 58 |
| 30 Jun 23 | 420 | 120 | 102 | 61 |
| 31 Mar 23 | 512 | 178 | 101 | 71 |
| 31 Dec 22 | 447 | 151 | 97 | 72 |
| 30 Sep 22 | 373 | 143 | 86 | 57 |
| 30 Jun 22 | 360 | 133 | 79 | 49 |
| 31 Mar 22 | 267 | 78 | 81 | 36 |
| 31 Dec 21 | 327 | 120 | 84 | 31 |
| 31 Dec 20 | 1,037 | 571 | 153 | 59 |
| 31 Dec 19 | 138 | 21 | 66 | 21 |
| 31 Dec 18 | 79 | 17 | 34 | 11 |
Quality Earnings: 688253 has high quality earnings.
Growing Profit Margin: 688253's current net profit margins (46.1%) are higher than last year (26.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688253's earnings have grown by 7.4% per year over the past 5 years.
Accelerating Growth: 688253's earnings growth over the past year (203.1%) exceeds its 5-year average (7.4% per year).
Earnings vs Industry: 688253 earnings growth over the past year (203.1%) exceeded the Medical Equipment industry -8.8%.
Return on Equity
High ROE: 688253's Return on Equity (16.2%) is considered low.